Navigation Links
Eidogen-Sertanty Licenses TIP to the FDA
Date:12/8/2009

SAN DIEGO, Dec. 8 /PRNewswire/ -- Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, announced today they have licensed their Target Informatics Platform (TIP) to the U.S. Food and Drug Administration's National Center for Toxicological Research (NCTR).

Under the terms of the license, scientists within NCTR will have access to the complete TIP structural knowledgebase via onlineTIP as well as access to the TIP/Workgroup technology for internal research. Eidogen-Sertanty will also participate in several NCTR-led projects including the multi-year PADRE project (MAQC-IV), which is focusing on the modeling of drug-protein interactions to identify new genetic variations that may lead to serious adverse drug reactions.

"We're extremely pleased to have licensed the TIP technology to the FDA/NCTR," said Dr. Steven Muskal, Eidogen-Sertanty's Chief Executive Officer. "We very much look forward to having a positive impact in the FDA's effort to predict serious adverse drug reactions at the individual patient level."


Eidogen-Sertanty contact:

Steve Muskal
760-651-2885
pr@eidogen-sertanty.com

About Eidogen-Sertanty

Eidogen-Sertanty, formed in March 2005 from the merger of Eidogen and Sertanty, is a privately held company providing pioneering knowledge-driven discovery solutions to biotechnology and pharmaceutical organizations. Eidogen-Sertanty's unique and powerful suite of software, databases, and drug discovery services enable customers and collaborators to apply a knowledge-driven discovery approach to a variety of workflows and processes, including target selection and prioritization, library building and compound prioritization, and lead design and optimization. To find out more about Eidogen-Sertanty and their products and services, please visit www.eidogen-sertanty.com.

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

SOURCE Eidogen-Sertanty


'/>"/>
SOURCE Eidogen-Sertanty
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Global Med Technologies(R), Inc. Licenses EdgeLab to Seven Laboratories at University Hospital of Reims, France
2. GeneGo Licenses MetaCore to Proteostasis Therapeutics
3. Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology
4. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
5. Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
6. ImmunoVaccine Technologies Licenses Immunotopes Breast, Ovarian and Prostate Cancer Antigens
7. Syngenta Licenses Chromatin Gene Stacking Technology for Sugar Cane
8. Calvert Research Licenses Novel Technology to Treat Age Related Macular Degeneration from Tulane University
9. Nanosys Licenses Nanowire Technology to QuantuMDx Group for Next Generation Diagnostic and Sequencing Technologies
10. Global Med Technologies(R) Licenses 90th Site in the Southeastern U.S.
11. Implicit Licenses Clinical Stage Antibody Program From Lilly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... The American Academy of Thermology ... offering its 2016 AAT Member Certification Qualification Course for Technicians via a two part ... which will include a detailed review of hardware, software, and camera setup/operations, aligns with ...
(Date:2/9/2016)... Feb. 9, 2016 This market research report ... and future prospects of the market in terms of ... companies engaged in the manufacture of microbiology culture media ... with a market snapshot providing the overall information of ... report. This section also provides the overall information and ...
(Date:2/9/2016)... Feb. 9, 2016 ... 2016", report provides in depth insights on ... around the Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors. ... in various stages of development including Discovery, ... III and Preregistration. Report covers the product ...
(Date:2/8/2016)... --> ... oncology company developing next generation cancer therapeutics that ... that chairman emeritus of Tata Sons Limited, Mr ... as part of the first close of Invictus,s ... Capital and Aarin Capital. http://photos.prnewswire.com/prnh/20150923/766442 ) ...
Breaking Biology Technology:
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first day ... announced plans to develop a first of its kind ... of IBM Watson. In the first application of ... (NYSE: IBM ), and Welltok will create a ... assessments with cognitive analytics, delivered on Welltok,s health optimization ...
(Date:1/28/2016)... Jan. 28, 2016 Synaptics (NASDAQ: SYNA ), a ... its second quarter ended December 31, 2015. ... of fiscal 2016 increased 2 percent compared to the comparable quarter ... of fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... income for the first quarter of fiscal 2016 grew 9 percent ...
(Date:1/25/2016)... BLUE BELL, Pa. , Jan. 25, 2016   Unisys ... facial recognition system at John F. Kennedy (JFK) International Airport, ... and Border Protection (CBP) identify imposters attempting to enter ... or do not belong to them. pilot testing ... rolled out initially at three terminals at JFK during January 2016. ...
Breaking Biology News(10 mins):